FT-555

N/A

Report date: 2022/12/07 17:48:36

Base Information

Drug NameFT-555
Drug Alias NameFT-555
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionG-protein coupled receptor family C group 5member D modulatorsImmunostimulantsNatural killer cells stimulants +[4] 
TargetsG-protein coupled receptor family C group 5member DLymphocyte differentiation antigen CD38
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesFate Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesFate Therapeutics IncJanssen Biotech Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A